These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 20140009)

  • 1. Premetastatic milieu explained by TLR4 agonist-mediated homeostatic inflammation.
    Maru Y
    Cell Mol Immunol; 2010 Mar; 7(2):94-9. PubMed ID: 20140009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toll-like receptor 4 activation in cancer progression and therapy.
    Oblak A; Jerala R
    Clin Dev Immunol; 2011; 2011():609579. PubMed ID: 22110526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Role of TLR4 in Chemotherapy-Driven Metastasis.
    Ran S
    Cancer Res; 2015 Jun; 75(12):2405-10. PubMed ID: 25998620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inflammation-associated premetastatic niche formation.
    Deguchi A; Maru Y
    Inflamm Regen; 2022 Jul; 42(1):22. PubMed ID: 35780158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cobalt Alloy Implant Debris Induces Inflammation and Bone Loss Primarily through Danger Signaling, Not TLR4 Activation: Implications for DAMP-ening Implant Related Inflammation.
    Samelko L; Landgraeber S; McAllister K; Jacobs J; Hallab NJ
    PLoS One; 2016; 11(7):e0160141. PubMed ID: 27467577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of toll-like receptor 4. Insights from x-ray crystallography and molecular modeling.
    Klett J; Reeves J; Oberhauser N; Pérez-Regidor L; Martín-Santamaria S
    Curr Top Med Chem; 2014; 14(23):2672-83. PubMed ID: 25515751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Site-specific contribution of Toll-like receptor 4 to intestinal homeostasis and inflammatory disease.
    Bruning EE; Coller JK; Wardill HR; Bowen JM
    J Cell Physiol; 2021 Feb; 236(2):877-888. PubMed ID: 32730645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human Toll-Like Receptor 4 (hTLR4): Structural and functional dynamics in cancer.
    Mishra V; Pathak C
    Int J Biol Macromol; 2019 Feb; 122():425-451. PubMed ID: 30365988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Local interleukin-1-driven joint pathology is dependent on toll-like receptor 4 activation.
    Abdollahi-Roodsaz S; Joosten LA; Koenders MI; van den Brand BT; van de Loo FA; van den Berg WB
    Am J Pathol; 2009 Nov; 175(5):2004-13. PubMed ID: 19834062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of proteinase-activated receptor 2 and TLR4 signal transduction: a novel paradigm for receptor cooperativity.
    Rallabhandi P; Nhu QM; Toshchakov VY; Piao W; Medvedev AE; Hollenberg MD; Fasano A; Vogel SN
    J Biol Chem; 2008 Sep; 283(36):24314-25. PubMed ID: 18622013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The science of vaccine adjuvants: advances in TLR4 ligand adjuvants.
    Reed SG; Hsu FC; Carter D; Orr MT
    Curr Opin Immunol; 2016 Aug; 41():85-90. PubMed ID: 27392183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endogenous ligands of TLR4 promote unresolving tissue fibrosis: Implications for systemic sclerosis and its targeted therapy.
    Bhattacharyya S; Varga J
    Immunol Lett; 2018 Mar; 195():9-17. PubMed ID: 28964818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toll-like receptor 4 senses oxidative stress mediated by the oxidation of phospholipids in extracellular vesicles.
    Manček-Keber M; Frank-Bertoncelj M; Hafner-Bratkovič I; Smole A; Zorko M; Pirher N; Hayer S; Kralj-Iglič V; Rozman B; Ilc N; Horvat S; Jerala R
    Sci Signal; 2015 Jun; 8(381):ra60. PubMed ID: 26082436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alteration of Toll-like receptor 4 activation by 4-hydroxy-2-nonenal mediated by the suppression of receptor homodimerization.
    Kim YS; Park ZY; Kim SY; Jeong E; Lee JY
    Chem Biol Interact; 2009 Nov; 182(1):59-66. PubMed ID: 19627980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postulates for validating TLR4 agonists.
    Manček-Keber M; Jerala R
    Eur J Immunol; 2015 Feb; 45(2):356-70. PubMed ID: 25476977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergism of toll-like receptor 2 (TLR2), TLR4, and TLR6 ligation on the production of tumor necrosis factor (TNF)-alpha in a spontaneous arthritis animal model of interleukin (IL)-1 receptor antagonist-deficient mice.
    Jung YO; Cho ML; Lee SY; Oh HJ; Park JS; Park MK; Park MJ; Ju JH; Kim SI; Park SH; Kim HY; Min JK
    Immunol Lett; 2009 Apr; 123(2):138-43. PubMed ID: 19428561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TLR4-activated microglia require IFN-γ to induce severe neuronal dysfunction and death in situ.
    Papageorgiou IE; Lewen A; Galow LV; Cesetti T; Scheffel J; Regen T; Hanisch UK; Kann O
    Proc Natl Acad Sci U S A; 2016 Jan; 113(1):212-7. PubMed ID: 26699475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intestinal expression of Fas and Fas ligand is upregulated by bacterial signaling through TLR4 and TLR5, with activation of Fas modulating intestinal TLR-mediated inflammation.
    Fernandes P; O'Donnell C; Lyons C; Keane J; Regan T; O'Brien S; Fallon P; Brint E; Houston A
    J Immunol; 2014 Dec; 193(12):6103-13. PubMed ID: 25378591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of toll-like receptor 4 (TLR4) in cancer progression: A possible therapeutic target?
    Kashani B; Zandi Z; Pourbagheri-Sigaroodi A; Bashash D; Ghaffari SH
    J Cell Physiol; 2021 Jun; 236(6):4121-4137. PubMed ID: 33230811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses.
    Goff PH; Hayashi T; Martínez-Gil L; Corr M; Crain B; Yao S; Cottam HB; Chan M; Ramos I; Eggink D; Heshmati M; Krammer F; Messer K; Pu M; Fernandez-Sesma A; Palese P; Carson DA
    J Virol; 2015 Mar; 89(6):3221-35. PubMed ID: 25568203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.